Logo

IART

Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation • NASDAQ
$13.12 ▲ 0.00% (+0.00)
Market Cap $1.02 B
52w High $27.13
52w Low $10.87
Dividend Yield 0%
P/E -2.03
Volume 185.70K
Outstanding Shares 77.89M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $402.062M ▼ $185.817M ▼ $-5.404M ▲ -1.344% ▲ $-0.07 ▲ $54.063M ▲
Q2-2025 $415.605M ▲ $722.006M ▲ $-484.073M ▼ -116.474% ▼ $-6.33 ▼ $-472.218M ▼
Q1-2025 $382.653M ▼ $209.929M ▼ $-25.293M ▼ -6.61% ▼ $-0.33 ▼ $25.967M ▼
Q4-2024 $442.646M ▲ $213.445M ▲ $19.435M ▲ 4.391% ▲ $0.25 ▲ $79.114M ▲
Q3-2024 $380.834M $208.388M $-10.695M -2.808% $-0.14 $34.972M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $267.879M ▲ $3.646B ▼ $2.609B ▼ $1.038B ▼
Q2-2025 $253.608M ▼ $3.668B ▼ $2.629B ▲ $1.039B ▼
Q1-2025 $273.295M ▼ $4.053B ▲ $2.529B ▲ $1.524B ▼
Q4-2024 $273.567M ▼ $4.037B ▼ $2.492B ▼ $1.545B ▲
Q3-2024 $277.598M $4.066B $2.544B $1.522B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.404M ▲ $40.906M ▲ $-15.588M ▲ $-10.245M ▲ $14.272M ▲ $25.75M ▲
Q2-2025 $-484.073M ▼ $8.919M ▲ $-21.648M ▲ $-21.139M ▼ $-21.19M ▼ $-11.227M ▲
Q1-2025 $0 ▼ $-11.257M ▼ $-35.92M ▼ $35.377M ▲ $-7.271M ▼ $-40.177M ▼
Q4-2024 $19.435M ▲ $50.74M ▲ $-4.249M ▲ $-7.15M ▲ $31.218M ▲ $11.187M ▲
Q3-2024 $-10.696M $22.485M $-10.396M $-19.915M $-79K $-7.161M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Codman Specialty Surgical
Codman Specialty Surgical
 $310.00M ▲$280.00M ▼$300.00M ▲$290.00M ▼
Tissue Technologies
Tissue Technologies
 $130.00M ▲$100.00M ▼$110.00M ▲$110.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown modestly over the last several years, with only a brief pause, showing that demand for Integra’s products has been fairly resilient. The main story, however, is pressure on profitability. Gross profit has held up reasonably well, but operating margins have narrowed meaningfully, and what used to be solid profits has recently slipped to a small net loss. This suggests higher costs, integration expenses, or operational disruptions are weighing on earnings, even as the top line trends upward. The pattern is one of a business with stable sales but under strain to turn those sales into strong bottom‑line results.

Balance Sheet

Balance Sheet The balance sheet shows a company that has been growing its asset base but leaning more on borrowing to do so. Total assets have climbed steadily, while debt has increased and cash balances have drifted down from earlier peaks. Equity has grown over the longer period but has softened more recently, reflecting weaker profitability. Overall, Integra still has a meaningful equity cushion, yet its financial profile has become more leveraged and somewhat less flexible than a few years ago, making efficient execution more important.

Cash Flow

Cash Flow Cash generation has moved in the same direction as earnings: solid a few years ago, now visibly weaker. Operating cash flow has stepped down from earlier strengths, and free cash flow has shrunk to only a thin positive level after capital spending. The company is still investing in its business, but with less cash left over, there is less room for aggressive debt reduction or large shareholder returns. The trend highlights the need for Integra to restore margin and working‑capital efficiency to rebuild cash flow strength.

Competitive Edge

Competitive Edge Integra occupies defensible, specialized niches in regenerative medicine and complex surgical solutions, particularly in neurosurgery and reconstructive procedures. Its position is supported by recognized brands, long‑standing surgeon relationships, and a portfolio of clinically differentiated products. Patents, regulatory know‑how, and a broad global distribution network create meaningful barriers for new entrants. At the same time, the company competes against larger medical device players, so maintaining share depends on continued innovation, strong clinical outcomes, and reliable product supply. The divestiture of lower‑growth assets and focus on higher‑value areas sharpen its strategic edge but also concentrate execution risk in these core segments.

Innovation and R&D

Innovation and R&D Innovation is a clear strength. Integra’s regenerative skin and tissue platforms, neurosurgical tools, and expanding ear‑nose‑throat portfolio stem from sustained R&D and selective acquisitions. The company is investing in upgraded manufacturing, like the new facility for key tissue products, and is benefiting from more favorable reimbursement for advanced skin substitutes. These steps can support long‑term growth and margin improvement if executed well. However, they also bring short‑term complexity and cost, which helps explain recent earnings pressure. Future value will hinge on successfully launching new products, integrating acquisitions such as the ENT business, and scaling the new manufacturing footprint without quality or supply setbacks.

Summary

Integra LifeSciences blends attractive strategic positioning with currently mixed financial performance. On the positive side, it operates in specialized, clinically demanding markets where its products are well‑regarded and protected by technology, patents, and relationships. Its focus on regenerative medicine, neurosurgery, and now ENT gives it exposure to structural healthcare growth drivers and potential reimbursement tailwinds. On the more cautious side, profitability and cash flow have weakened even as revenue has inched higher, and leverage has risen, leaving less margin for error. Going forward, the key questions are whether Integra can restore its historical earnings strength, improve cash generation, and smoothly execute on manufacturing consolidation and acquisitions while preserving the innovative edge that underpins its competitive moat.

NEWS

November 25, 2025 · 8:30 AM UTC

Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access

Read more

November 11, 2025 · 4:15 PM UTC

Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries

Read more

October 30, 2025 · 6:00 AM UTC

Integra LifeSciences Reports Third Quarter 2025 Financial Results

Read more

October 15, 2025 · 8:30 AM UTC

Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025

Read more

October 8, 2025 · 8:30 AM UTC

Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting

Read more